

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification:</b> <b>A61K 38/13, 9/16, 9/51</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/31202</b> <b>(43) International Publication Date:</b> 10 October 1996 (10.10.96)
<b>(21) International Application Number:</b> PCT/IE96/00017 <b>(22) International Filing Date:</b> 2 April 1996 (02.04.96)  <b>(30) Priority Data:</b> 950233 3 April 1995 (03.04.95) IE  <b>(71) Applicant:</b> ELAN CORPORATION, PLC [IE/IE]; Monksland Industrial Estate, Athlone, County Westmeath (IE). <b>(72) Inventor:</b> RAMTOOLA, Zebunnissa; 163 Charlemont, Griffith Avenue, Dublin 9 (IE). <b>(74) Agent:</b> ANNE RYAN & CO.; 60 Northumberland Road, Ballsbridge, Dublin 4 (IE).		<b>(81) Designated States:</b> AU, CA, JP, NZ, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> CONTROLLED RELEASE BIODEGRADABLE MICRO- AND NANOSPHERES CONTAINING CYCLOSPORIN  <b>(57) Abstract</b> <p>A controlled release pharmaceutical formulation which comprises cyclosporin entrapped in a biodegradable polymer to form microspheres or nanospheres such that the cyclosporin is substantially in an amorphous state and the biodegradable polymer comprises greater than 12.5 % w/w poly(lactide). The biodegradable polymer is suitably poly-D,L-lactide or a blend of poly-D,L-lactide and poly-D,L-lactide-co-glycolide. Additionally, an enteric coating can be applied to the microspheres or nanospheres or to the oral dosage form incorporating the microspheres or nanospheres to protect the formulation while it passes through the stomach. A particularly suitable formulation comprises 50 % w/w cyclosporin-loaded 80:20 blend of poly-D,L-lactide-co-glycolide to poly-D,L-lactide micro- and/or nanospheres. This formulation has the combined properties of nearly complete but relatively slow release of cyclosporin within 8 hours and is useful for targeting cyclosporin to the small intestine when administered orally.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## Description

### Controlled release biodegradable micro- and nanospheres containing cyclosporin

#### Technical Field

- 5           This invention relates to controlled release biodegradable micro- and nanosphere formulations and, in particular, biodegradable formulations containing cyclosporin or cyclosporin analogues.

#### Background Art

- 10           Cyclosporin A is a lipophilic cyclic undecapeptide of molecular weight 1203 isolated from the fungus *Tolypocladium inflatum* Gams which produces calcium dependent, specific and reversible inhibition of transcription of interleukin-2 and several other cytokines, most notably in T helper lymphocytes. Because of its immunosuppressive properties, it is widely used as first line therapy in the prophylaxis and treatment
- 15           of transplant rejection and various autoimmune diseases. In patients with severe disease refractory to standard treatment, oral cyclosporin is an effective therapy in acute ocular Behcet's syndrome, endogenous uveitis, psoriasis, atopic dermatitis, rheumatoid arthritis, active Crohn's disease and nephrotic syndrome. This drug has also been used to treat
- 20           patients with moderate or severe aplastic anaemia who are ineligible for bone marrow transplantation and those with primary biliary cirrhosis. Cyclosporin may be effective in patients with intractable pyoderma gangrenosum, polymyositis/dermatomyositis or severe, corticosteroid-dependent asthma. Cyclosporin is known to have a very specific effect
- 25           on T-cell proliferation although the precise mechanism remains unclear. It has been shown to be an effective modifier of multidrug resistance in human and rodent cells. A number of non-immunosuppressive analogues of cyclosporin A have been shown to have resistance modifier activity and some are more potent than the
- 30           parent compound.

Hypertrichosis, gingival hyperplasia and neurological and gastrointestinal effects are the most common adverse events in cyclosporin recipients. Also, changes in laboratory variables indicating renal dysfunction are relatively common.

5 Cyclosporin is highly lipophilic, poorly water soluble and, therefore, typically supplied as an olive oil or peanut oil solution for clinical use. However, the bioavailability of cyclosporin from such oily solutions is very low and gives rise to great intersubject variation with reported systemic availability ranging from 4 to 25% (Takada, K. et al,  
10 *J. Pharmacobio-Dyn.*, 11:80-7 (1988)). The bioavailability of cyclosporin has been reported to be dependent on food, bile and other interacting factors (Fahr, A., *Clin. Pharmacokinetics*, 24:472-95 (1993)). In a recent study in which a microemulsion preparation of cyclosporin was administered locally to different parts of the small and  
15 large intestine (duodenum, jejunum, ileum and colon descendens), cyclosporin was found to be absorbed predominantly in the small intestine (Drewe, J. et al., *Br. J. Clin. Pharmac.*, 33:39-43 (1992)).

Cyclosporin A has been encapsulated in poly-D,L-lactide-co-glycolide microspheres and nanospheres (Alonso, J., *Proceed. Intern. Symp. Control. Rel. Bioact. Mat.*, 20:109-10 (1993)). However, these  
20 microspheres and nanospheres failed to release more than 50% of the entrapped cyclosporin within a 28 day period.

Thus, to address the toxicity and intra- and intersubject variation in availability issues, there exists a need for a cyclosporin  
25 pharmaceutical formulation with increased bioavailability. Further, there exists a need for a cyclosporin formulation which efficiently targets cyclosporin to the absorption site(s) for cyclosporin.

### Disclosure of Invention

30 This invention provides a controlled release pharmaceutical formulation, which comprises cyclosporin entrapped in a biodegradable polymer to form microspheres or nanospheres, wherein the cyclosporin

is substantially in an amorphous state and wherein the biodegradable polymer comprises greater than 12.5% w/w poly(lactide).

As used herein, the term "cyclosporin" refers to cyclosporin A and analogues of cyclosporin A having similar physical properties.

5           As used herein, the term "biodegradable" as applied to polymers means polymers which are degradable *in vivo* either enzymatically or non-enzymatically to produce biocompatible or non-toxic by-products which can be further metabolized or excreted *via* normal physiological pathways. Examples of synthetic biodegradable polymers include  
10 poly(lactide); poly(glycolide) and poly(lactide-co-glycolide), stereoisomers (i.e., D, L), racemic mixtures, and polymer mixtures thereof.

          The biodegradable polymer is suitably poly-D,L-lactide or a blend of poly-D,L-lactide and poly-D,L-lactide-co-glycolide, provided  
15 that the blend contains enough poly(lactide) so that the entrapped cyclosporin is substantially in an amorphous state.

          Surprisingly, this invention discloses that release of cyclosporin from poly(lactide) microspheres or nanospheres is considerably higher than release from corresponding poly(lactide-co-glycolide)  
20 microspheres or nanospheres. This increase in release, and subsequent bioavailability, is correlated with cyclosporin being present in a substantially amorphous form in the poly(lactide) formulations as opposed to the presence of crystalline cyclosporin in the poly(lactide-co-glycolide) formulations.

25           The controlled release pharmaceutical formulation of this invention suitably has a dissolution profile measured under sink conditions at 37°C for cyclosporin substantially as follows:

- a) 40-80% release within 1 hour;
- b) 75-95% release within 4 hours; and
- 30 c)  $\geq$  80% within 8 hours.

Thus, this invention provides cyclosporin-containing microspheres or nanospheres that are capable of releasing greater than 80%, preferably greater than 90%, of the entrapped drug within an 8 hour period in a controlled fashion. When these microspheres or nanospheres are orally administered to a subject, particularly a human, the release of cyclosporin in the stomach is minimized to avoid bioavailability variations due to the presence of food, bile or other factors. However, the release of cyclosporin is targeted to the small intestine, the site at which cyclosporin is predominantly absorbed.

The biodegradable micro- and nanospheres preferably contain 20 to 80% w/w cyclosporin, more especially 45-55% w/w cyclosporin.

A particularly suitable formulation comprises 50% w/w cyclosporin-loaded 80:20 blend of poly-D,L-lactide-co-glycolide to poly-D,L-lactide micro- and/or nanospheres. This formulation has the combined properties of nearly complete but relatively slow release of cyclosporin within 8 hours and is useful for targeting cyclosporin to the small intestine when administered orally.

The micro- and nanospheres in accordance with the invention are suitably incorporated into oral dosage forms, such as capsules, tablets, powders including powders capable of effervescing upon addition of water, or suspensions. Additionally, an enteric coating can be applied to the microspheres or nanospheres or to the oral dosage form to protect the formulation while it passes through the stomach to further target release of cyclosporin to the small intestine. Alternatively, the micro- and nanospheres in accordance with the invention can be administered parenterally to release greater than 80%, preferably greater than 90%, of the entrapped cyclosporin in a controlled manner over an 8 hour period.

Thus, for convenient and effective oral administration, effective amounts of the micro- and/or nanospheres of this invention can be tableted with one or more excipient(s), encased in capsules such as gel capsules, formulated with ingredients which, upon addition of water,

provide an effervescent solution, and suspended in a liquid solution and the like. The micro- and nanospheres can be suspended in a saline solution or the like for parenteral administration.

It will be appreciated that the pharmaceutical formulations in accordance with the invention can be used *inter alia* to provide immunosuppression in organ transplant patients and to treat autoimmune diseases. Suitably, the formulation of this invention is administered to humans such that the whole blood levels of cyclosporin A are maintained between 200 and 500 ng/mL, which currently is believed to be the level at which serious renal toxicity is unusual. Thus, a suitable dose of the formulation of this invention is less than 5 mg/kg/day of cyclosporin entrapped in the micro- or nanospheres.

Biodegradable micro- and nanospheres containing 20 to 80% w/w cyclosporin (Leiras) are suitably prepared herein by a solvent evaporation/extraction procedure from an emulsion system (Ramtoola, Z. et al., *J. Microencapsulation*, 9:415-23 (1992)). The polymers used are suitably poly-D,L-lactide having a  $M_w$  of 16,000 and i.v. of 0.2 dl/g (R-203; Boehringer Ingelheim) and poly-D,L-lactide-co-glycolide 50:50 of i.v. 0.5 dl/g (RG-504; Boehringer Ingelheim).

For instance, cyclosporin and the encapsulating polymer are dissolved in methylene chloride. Suitable methylene chloride to polymer ratios are 1-2 ml methylene chloride/g of R-203 and 3 ml of methylene chloride/g of RG-504. This drug/polymer solution is then suitably emulsified in an aqueous PVA solution (suitably 0.27%) in a ratio of about 10 ml of the drug/polymer solution to 100 ml of the PVA solution and mixed at high speed (suitably 20,000-24,000 rpm) for 2 min followed by stirring at 1000 rpm for 2 hr. The particles are recovered by centrifugation and dried overnight in a vacuum oven.

In the following Examples the particles produced were characterized by scanning electron microscopy (S360, Leica, Cambridge) and were sized using a Malvern 2600 Laser Sizer. The particles were also characterized by X-ray diffraction (Daco-MP 500,

Siemens). The drug content of the microparticles was assayed by HPLC using a Novapak C8 column at 70°C using a mobile phase of acetonitrile:water:methanol: phosphoric acid (900:525:75:0.075) at a flow rate of 2 ml/min with UV detection at 210 nm.

5           The solubility of cyclosporin was measured at 37°C in increasing concentrations of sodium lauryl sulfate (SLS) solutions to determine sink conditions for dissolution studies. As was expected, the solubility of cyclosporin (S) was found to increase linearly with increasing SLS concentration (M) according to the following equation:

10  $S = S_0 + K.M$

where  $S_0$  is the intrinsic solubility of cyclosporin and  $K$  is the solubilizing capacity. A value of 0.284 with a correlation coefficient of 0.997 was obtained for  $K$  and an SLS concentration of  $\geq 0.3\%$  (w/v) was found to provide sink conditions. *In vitro* release studies of the cyclosporin were carried out, under sink conditions, using a VanKel dissolution bath and dissolution samples were analyzed by HPLC.

### Brief Description of the Drawings

Figure 1 shows the increasing release of cyclosporin from cyclosporin-loaded poly-D,L-lactide microspheres as the drug loading is increased from 25% to 30% to 40% to 50% to 70% to 80% (w/w); and

Figure 2 shows the unexpected greater release of cyclosporin from cyclosporin-loaded poly-D,L-lactide microspheres or poly-D,L-lactide:poly-D,L-lactide-co-glycolide microspheres in which the cyclosporin is predominantly in the amorphous state (i.e., microspheres having a poly-D,L-lactide-co-glycolide to poly-D,L-lactide ratio of 0:100, 50:50, 75:25 and 80:20) as opposed to the slower release from cyclosporin-loaded microspheres in which crystalline cyclosporin is present (i.e.,



microspheres having a poly-D,L-lactide-co-glycolide to poly-D,L-lactide ratio of 87.5:12.5 and 100:0).

### Modes for Carrying Out the Invention

5       The invention will be further illustrated by the following Examples.

#### Example 1

##### Cyclosporin-loaded poly-D,L-lactide microspheres

10       The characteristics of cyclosporin-loaded microparticles prepared in the manner described above using R-203 as the encapsulating polymer (emulsion mixed at 20,500 rpm for 2 min) are shown in Table 1. The drug entrapment efficiency of the particles produced was independent of the drug loading and was higher than 93% in all cases. Photomicrographs show the surface of the particles produced to be smooth and drug free for this range of drug loadings.

15       Scanning electron microscopy showed the particles to be below 5 microns in diameter. Particle size analysis gave larger D<sub>50%</sub> values for the particles, probably a result of particle aggregation during this measurement. X-ray diffraction of the microspheres showed that cyclosporin was present in an amorphous state for all of these drug

20       loadings.

TABLE 1				
Sample	Starting Drug Loading (w/w %)	Assayed Drug Loading (w/w %)	Entrapment Efficiency (%)	D <sub>50</sub> (μm)
CYC1	25	25.97	103.88	19.20
CYC2	30	38.39	127.97	8.43
CYC3	40	37.40	93.50	17.50
CYC4	50	46.86	93.72	24.98
CYC5	70	66.54	95.06	5.76
CYC6	80	79.67	99.59	10.88

The release of cyclosporin from the microparticles was found to be faster the higher the drug loading and is shown in Figure 1. An initial burst in release, which increased with increasing drug loading, was observed for all systems studied. This burst effect is usually associated with drug located at or near the surface of the microsphere and would be expected to increase with increasing drug loading of the microspheres. Cyclosporin release was consistent with a diffusion controlled mechanism at the higher drug loadings (>40%). At low drug loadings, initial release (over the first 24 hours) was by diffusion. Subsequent cyclosporin release from the microspheres was slower and probably controlled by polymer degradation.

### Example 2

#### Cyclosporin-loaded poly-D,L-lactide-co-glycolide: poly-D,L-lactide microspheres

Cyclosporin-loaded microspheres at the 50% w/w drug loading were prepared in the manner described above using the more hydrophilic RG-504 polymer and various blends of RG-504 and R-203